Oral MS drug BG-12 significantly reduced MS relapses and disability progression
Biogen Idec BIIB today announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS).
Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years compared with placebo.
Detailed data from DEFINE will be presented at the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) in Amsterdam, including a platform presentation on Friday, October 21, 2011 at 9:30 a.m. CEST.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679
Oral MS drug BG-12 significantly reduced MS relapses
Oral MS drug BG-12 significantly reduced MS relapses
MS-UK - http://www.ms-uk.org/
- Vikingquest
- Family Member
- Posts: 86
- Joined: Mon Jul 04, 2011 2:00 pm
Re: Oral MS drug BG-12 significantly reduced MS relapses
This is great news, no? When will it be available in the UK?
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 664 Views
-
Last post by frodo
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 170 Views
-
Last post by NHE
-
- 0 Replies
- 558 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif
-
- 0 Replies
- 167 Views
-
Last post by DIM
-
- 2 Replies
- 1112 Views
-
Last post by DIM
-
- 1 Replies
- 2016 Views
-
Last post by raceya